Allograft rejection requires STAT5a/b-regulated antiapoptotic activity in T cells but not B cells

Journal of Immunology

Volumn 176, Issue 1, 2006, Pages 128-137

  Zhang, Ye ^a   Kirken, Robert A ^b   Furian, Lucrezia ^a   Janczewska, Slawa ^a   Qu, Xiumei ^a   Hancock, Wayne W ^c   Wang, Mouer ^a   Tejpal, Neelam ^a   Kerman, Ronald ^a   Kahan, Barry D ^a   Stepkowski, Stanislaw M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CASPASE; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C4D; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; RAG1 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA REPAIR; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMORAL IMMUNITY; IN VITRO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MICROARRAY ANALYSIS; MOUSE; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECIPIENT; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING; WILD TYPE;

EID: 29644441041     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.1.128     Document Type: Article

References (52)

1. Appleman, L. J., and V. A. Boussiotis. 2003. T cell anergy and costimulation. Immunol. Rev. 192: 161-180.
2. Leonard, W. J., and J. J. O'Shea. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16: 293-322.
3. Kane, L. P., J. Lin, and A. Weiss. 2000. Signal transduction by the TCR for antigen. Curr. Opin. Immunol. 12: 242-249.
4. Leonard, W. J. 1996. STATs and cytokine specificity. Nat. Med. 2: 968-969.
5. Zhou, Y. J., K. S. Magnuson, T. P. Cheng, M. Gadina, D. M. Frucht, J. Galon, F. Candotti, R. L. Geahlen, P. S. Changelian, and J. J. O'Shea. 2000. Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation. Mol. Cell. Biol. 20: 4371-4380.
6. Nelson, B. H., and D. M. Willerford. 1998. Biology of the interleukin-2 receptor. Adv. Immunol. 70: 1-81.
7. Nagy, Z. S., Y. Wang, R. A. Erwin-Cohen, J. Aradi, B. Monia, L. H. Wang, S. M. Stepkowski, H. Rui, and R. A. Kirken. 2002. Interleukin-2 family cytokines stimulate phosphorylation of the Pro-Ser-Pro motif of Stat5 transcription factors in human T cells: resistance to suppression of multiple serine kinase pathways. J. Leukocyte Biol. 72: 819-828.
8. Bromberg, J., and J. E. Darnell, Jr. 2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473.
9. Lin, J. X., and W. J. Leonard. 2000. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 19: 2566-2576.
10. Nagy, Z. S., J. Ross, H. Cheng, S. M. Stepkowski, and R. A. Kirken. 2004. Regulation of lymphoid cell apoptosis by Jaks and Stats. Crit. Rev. Immunol. 24: 87-110.
11. Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
12. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442.
13. Shimoda, K., J. van Deursen, M. Y. Sangster, S. R. Sarawar, R. T. Carson, R. A. Tripp, C. Chu, F. W. Quelle, T. Nosaka, D. A. Vignali, et al. 1996. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380: 630-633.
14. Thierfelder, W. E., J. M. van Deursen, K. Yamamoto, R. A. Tripp, S. R. Sarawar, R. T. Carson, M. Y. Sangster, D. A. Vignali, P. C. Doherty, G. C. Grosveld, and J. N. Ihle. 1996. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382: 171-174.
15. Kishimoto, K., V. M. Dong, S. Issazadeh, E. V. Fedoseyeva, A. M. Waaga, A. Yamada, M. Sho, G. Benichou, H. Auchincloss, Jr., M. J. Grusby, et al. 2000. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J. Clin. Invest. 106: 63-72.
16. Wakao, H., F. Gouilleux, and B. Groner. 1994. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 13: 2182-2191.
17. Liu, X., G. W. Robinson, F. Gouilleux, B. Groner, and L. Hennighausen. 1995. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Natl. Acad. Sci. USA 92: 8831-885.
18. Moriggl, R., D. J. Topham, S. Teglund, V. Sexl, C. McKay, D. Wang, A. Hoffmeyer, J. van Deursen, M. Y. Sangster, K. D. Bunting, et al. 1999. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10: 249-259.
19. Liu, X., G. W. Robinson, K. U. Wagner, L. Garrett, A. Wynshaw-Boris, and L. Hennighausen. 1997. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11: 179-186.
20. Udy, G. B., R. P. Towers, R. G. Snell, R. J. Wilkins, S. H. Park, P. A. Ram, D. J. Waxman, and H. W. Davey. 1997. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. USA 94: 7239-7244.
21. Chai, S. K., G. L. Nichols, and P. Rothman. 1997. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J. Immunol. 159: 4720-478.
22. Weber-Nordt, R. M., C. Egen, J. Wehinger, W. Ludwig, V. Gouilleux-Gruart, R. Mertelsmann, and J. Finke. 1996. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88: 809-816.
23. Lord, J. D., B. C. McIntosh, P. D. Greenberg, and B. H. Nelson. 1998. The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc. J. Immunol. 161: 4627-4633.
24. Matikainen, S., T. Sareneva, T. Ronni, A. Lehtonen, P. J. Koskinen, and I. Julkunen. 1999. Interferon-α activates multiple STAT proteins and up-regulates proliferation-associated IL-2Rα, c-myc, and pim-1 genes in human T cells. Blood 93: 1980-1991.
25. Behbod, F., Z. S. Nagy, S. M. Stepkowski, J. Karras, C. R. Johnson, W. D. Jarvis, and R. A. Kirken. 2003. Specific inhibition of Stat5a/b promotes apoptosis of IL-2-responsive primary and tumor-derived lymphoid cells. J. Immunol. 171: 3919-3927.
26. O'Shea, J. J. 1997. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7: 1-11.
27. Stepkowski, S. M., A. Raza-Ahmad, and W. R. Duncan. 1987. The role of class I and class II MHC antigens in the rejection of vascularized heart allografts in mice. Transplantation 44: 753-759.
28. Ferraresso, M., L. Tian, R. Ghobrial, S. M. Stepkowski, and B. D. Kahan. 1994. Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats. J. Immunol. 153: 3307-3318.
29. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
30. Benichou, G., P. A. Takizawa, P. T. Ho, C. C. Killion, C. A. Olson, M. McMillan, and E. E. Sercarz. 1990. Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides. J. Exp. Med. 172: 1341-136.
31. Ozkaynak, E., W. Gao, N. Shemmeri, C. Wang, J. C. Gutierrez-Ramos, J. Amaral, S. Qin, J. B. Rottman, A. J. Coyle, and W. W. Hancock. 2001. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat. Immunol. 2: 591-596.
32. Teglund, S., C. McKay, E. Schuetz, J. M. van Deursen, D. Stravopodis, D. Wang, M. Brown, S. Bodner, G. Grosveld, and J. N. Ihle. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93: 841-850.
33. Kieslinger, M., I. Woldman, R. Moriggl, J. Hofmann, J. C. Marine, J. N. Ihle, H. Beug, and T. Decker. 2000. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 14: 232-244.
34. + regulatory T cell homeostasis and the maintenance of self-tolerance. J. Immunol. 171: 3435-3441.
35. Pericle, F., R. A. Kirken, V. Bronte, G. Sconocchia, L. DaSilva, and D. M. Segal. 1997. Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. J. Immunol. 159: 2580-255.
36. Pericle, F., L. A. Pinto, S. Hicks, R. A. Kirken, G. Sconocchia, J. Rusnak, M. J. Dolan, G. M. Shearer, and D. M. Segal. 1998. HIV-1 infection induces a selective reduction in STAT5 protein expression. J. Immunol. 160: 28-31.
37. Cui, Y., G. Riedlinger, K. Miyoshi, W. Tang, C. Li, C. X. Deng, G. W. Robinson, and L. Hennighausen. 2004. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol. Cell. Biol. 24: 8037-8047.
38. Yamada, M., N. Ishii, H. Asao, K. Murata, C. Kanazawa, H. Sasaki, and K. Sugamura. 2002. Signal-transducing adaptor molecules STAM1 and STAM2 are required for T-cell development and survival. Mol. Cell. Biol. 22: 8648-8658.
39. Horikawa, K., H. Kaku, H. Nakajima, H. W. Davey, L. Hennighausen, I. Iwamoto, T. Yasue, A. Kariyone, and K. Takatsu. 2001. Essential role of Stat5 for IL-5-dependent IgH switch recombination in mouse B cells. J. Immunol. 167: 5018-5026.
40. Kouro, T., Y. Kikuchi, H. Kanazawa, K. Hirokawa, N. Harada, M. Shiiba, H. Wakao, S. Takaki, and K. Takatsu. 1996. Critical proline residues of the cytoplasmic domain of the IL-5 receptor α chain and its function in IL-5-mediated activation of JAK kinase and STATS. Int. Immunol. 8: 237-245.
41. + splenic B cells and peritoneal B-1 cells in response to IL-5 and CD38 ligation. Int. Immunol. 11: 915-923.
42. 1 switch recombination of B cells. Immunology 102: 289-300.
43. Habib, T., A. Nelson, and K. Kaushansky. 2003. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J. Allergy Clin. Immunol. 112: 1033-1045.
44. Yoshimoto, T., K. Okada, N. Morishima, S. Kamiya, T. Owaki, M. Asakawa, Y. Iwakura, F. Fukai, and J. Mizuguchi. 2004. Induction of IgG2a class switching in B cells by IL-27. J. Immunol. 173: 2479-2485.
45. Halloran, P. F., A. Wadgymar, S. Ritchie, J. Falk, K. Solez, and N. S. Srinivasa. 1990. The significance of the anti-class 1 antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 49: 85-91.
46. Feucht, H. E., H. Schneeberger, G. Hillebrand, K. Burkhardt, M. Weiss, G. Riethmuller, W. Land, and E. Albert. 1993. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 43: 1333-138.
47. Wasowska, B. A., Z. Qian, D. L. Cangello, E. Behrens, K. Van Tran, J. Layton, F. Sanfilippo, and W. M. Baldwin III. 2001. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 71: 727-736.
48. Kerman, R. H., B. Susskind, I. Buyse, P. Pryzbylowski, J. Ruth, S. Warnell, S. A. Gruber, S. Katz, C. T. Van Buren, and B. D. Kahan. 1999. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 68: 1855-188.
49. Kerman, R. H., B. Susskind, R. Buelow, J. Regan, P. Pouletty, J. Williams, K. Gerolami, D. H. Kerman, S. M. Katz, C. T. Van Buren, and B. D. Kahan. 1996. Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. Transplantation 62: 201-205.
50. Kerman, R. H., B. Susskind, D. Kerman, M. Lam, K. Gerolami, J. Williams, R. Kalish, M. Campbell, S. Katz, C. T. Van Buren, et al. 1998. Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease. J. Heart Lung Transplant. 17: 789-794.
51. Fiebeler, A., M. Mengel, S. Merkel, H. Haller, and A. Schwarz. 2003. Diffuse C4d deposition and morphology of acute humoral rejection in a stable renal allograft. Transplantation 76: 1132-113.
52. Fidler, M. E., J. M. Gloor, D. J. Lager, T. S. Larson, M. D. Griffin, S. C. Textor, T. R. Schwab, M. Prieto, S. L. Nyberg, M. B. Ishitani, et al. 2004. Histologic findings of antibody-mediated rejection in ABO blood-group- incompatible living-donor kidney transplantation. Am. J. Transplant. 4: 101-107.